• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA.

作者信息

Noth Imre, Oelberg David, Kaul Manika, Conoscenti Craig S, Raghu Ganesh

机构信息

University of Virginia School of Medicine, Charlottesville, VA, USA.

Western Connecticut Health Network, Danbury Hospital, Danbury, CT, USA.

出版信息

Eur Respir J. 2018 Jul 27;52(1). doi: 10.1183/13993003.02106-2017. Print 2018 Jul.

DOI:10.1183/13993003.02106-2017
PMID:29794129
Abstract
摘要

相似文献

1
Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA.美国尼达尼布治疗特发性肺纤维化患者的安全性和耐受性
Eur Respir J. 2018 Jul 27;52(1). doi: 10.1183/13993003.02106-2017. Print 2018 Jul.
2
Safety management of treatment with nintedanib in clinical practice of IPF.尼达尼布治疗特发性肺纤维化临床实践中的安全管理
Respir Investig. 2017 Jan;55(1):1. doi: 10.1016/j.resinv.2016.12.001.
3
Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.吡非尼酮和尼达尼布用于临床实践中的肺纤维化：耐受性和药物不良反应
Respirology. 2017 Aug;22(6):1171-1178. doi: 10.1111/resp.13024. Epub 2017 Mar 20.
4
Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.尼达尼布用于日本特发性肺纤维化患者：INPULSIS®随机试验的亚组分析
Respirology. 2017 May;22(4):750-757. doi: 10.1111/resp.12960. Epub 2016 Dec 20.
5
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.尼达尼布联合西地那非治疗特发性肺纤维化患者
N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15.
6
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.英国尼达尼布治疗特发性肺纤维化的成本效益分析。
Pharmacoeconomics. 2017 Apr;35(4):479-491. doi: 10.1007/s40273-016-0480-2.
7
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
Respir Res. 2018 Oct 19;19(1):203. doi: 10.1186/s12931-018-0907-8.
8
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.尼达尼布治疗特发性肺纤维化的疗效和安全性：更新。
Drugs R D. 2018 Mar;18(1):19-25. doi: 10.1007/s40268-017-0221-9.
9
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.关于尼达尼布治疗特发性肺纤维化且用力肺活量≤预测值50%患者的疗效和安全性的初步数据。
Lung. 2016 Oct;194(5):739-43. doi: 10.1007/s00408-016-9912-1. Epub 2016 Jul 4.
10
NICE guidance on nintedanib for treating idiopathic pulmonary fibrosis.英国国家卫生与临床优化研究所关于尼达尼布治疗特发性肺纤维化的指南。
Lancet Respir Med. 2016 Mar;4(3):176-7. doi: 10.1016/S2213-2600(16)00022-9. Epub 2016 Jan 27.

引用本文的文献

1
Disproportionality Analysis of Hepatotoxic and Gastrointestinal Adverse Events Associated With Nintedanib Using the Japanese Adverse Drug Event Report (JADER) Database.使用日本药品不良事件报告（JADER）数据库对与尼达尼布相关的肝毒性和胃肠道不良事件进行不成比例分析。
In Vivo. 2025 Jan-Feb;39(1):396-403. doi: 10.21873/invivo.13841.
2
Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan.尼达尼布在特发性肺纤维化患者中的真实世界安全性、耐受性和有效性：日本上市后监测的最终报告
Adv Ther. 2025 Feb;42(2):1075-1093. doi: 10.1007/s12325-024-03079-2. Epub 2024 Dec 23.
3
Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States.
特发性肺纤维化患者的真实世界抗纤维化治疗模式：美国两个大型医疗保健管理数据库的回顾性分析。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241280704. doi: 10.1177/17534666241280704.
4
Identification of immune patterns in idiopathic pulmonary fibrosis patients driven by PLA2G7-positive macrophages using an integrated machine learning survival framework.采用集成机器学习生存框架，鉴定由 PLA2G7 阳性巨噬细胞驱动的特发性肺纤维化患者的免疫模式。
Sci Rep. 2024 Sep 27;14(1):22369. doi: 10.1038/s41598-024-73625-z.
5
Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy.尼达尼布治疗特发性肺纤维化：在单一中心接受口服抗凝治疗患者的真实生活经历中的耐受性和安全性
Pharmaceuticals (Basel). 2023 Feb 16;16(2):307. doi: 10.3390/ph16020307.
6
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan.尼达尼布治疗特发性肺纤维化的真实世界安全性和耐受性：日本上市后监测的中期报告。
Adv Ther. 2023 Apr;40(4):1474-1493. doi: 10.1007/s12325-022-02411-y. Epub 2023 Jan 24.
7
Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic.在新冠疫情期间，尼达尼布与吡非尼酮在特发性肺纤维化患者中的药物相互作用
Pharmaceuticals (Basel). 2021 Aug 20;14(8):819. doi: 10.3390/ph14080819.
8
Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.基线血浆 KL-6 水平可预测接受尼达尼布治疗的特发性肺纤维化患者的不良结局：一项回顾性真实世界队列研究。
BMC Pulm Med. 2021 May 15;21(1):165. doi: 10.1186/s12890-021-01530-6.
9
The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.尼达尼布治疗间质性肺疾病的安全性：系统评价和随机对照试验的荟萃分析。
PLoS One. 2021 May 14;16(5):e0251636. doi: 10.1371/journal.pone.0251636. eCollection 2021.
10
Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis.吡非尼酮治疗特发性肺纤维化的安全性、有效性和耐受性的最新评估
Drug Healthc Patient Saf. 2020 May 7;12:85-94. doi: 10.2147/DHPS.S224007. eCollection 2020.